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INTRODUCTION

Veno-occlusive disease (VOD) of the liver is a potentially fatal complication of hematopoietic SCT (HSCT).
It is more common in the setting of allogeneic HSCT (allo-SCT) and is the result of the toxic damage on sinusoidal and hepatic cells caused by the conditioning regimen. It usually occurs during the first 20 days after graft infusion, although cases with late onset have been described. Clinical presentation is often manifested with hyperbilirubinemia, unexplained weight gain with or without ascites and painful hepatomegaly. 1 Diagnosis is based on the fulfillment of certain clinical criteria because liver biopsy is rarely performed in the presence of thrombocytopenia. 2, 3 Severity of VOD is recorded retrospectively with cases not resolved by day 100 and/or multiorgan failure characterized as severe, whereas cases with spontaneous recovery without any medical intervention are characterized as mild. 4 Risk factors for VOD development have been described and among others are: previous transplantation, pre-existing liver disease, intensity of the conditioning regimen and treatment with BU. 5 In the present article, we examined the incidence of moderateto-severe VOD in a large homogenous cohort of patients with hematologic malignancies treated with the same reduced intensity conditioning (RIC) in a single center. Table 1 . Patients were stratified to standard or high-risk categories according to the disease status pretransplant. In more detail, patients with AML or ALL in first CR, CML in first chronic phase, myelodysplastic syndrome without excess of blasts (refractory anemia or refractory anemia with ringed sideroblasts) and non-Hodgkin's lymphoma, Hodgkin's disease or multiple myeloma without chemorefractory disease were classified as standard risk patients. All the other patients were classified as high-risk patients. 6 Pre-existing liver disease was defined as the presence of liver infiltration by tumor, chronic viral infection or the presence of alcoholic liver disease.
PATIENTS AND METHODS
Donors
The donors were HLA-identical siblings in 173 cases, and a matchedunrelated donor (high-resolution HLA-A, -B, -C and DRB1-matched (eight out of eight alleles)) in 79 cases, respectively. One-locus mismatch family members and unrelated donors were used in 8 and 11 patients, respectively. PBSC was the source of stem cells in all 271 patients.
VOD of the liver
Diagnosis was confirmed using the modified Seattle criteria. 4 Briefly, diagnosis of VOD was suspected when at least two of the three occurred before day +21: (1) hyperbilirubinemia (42 mg/dL), (2) hepatomegaly or right upper quadrant pain and (3) ascites and/or sudden weight gain (42% of basal weight). Diagnosis of VOD was established whenever clinical and laboratory features could not be attributed to any other cause such as: sepsis, drug toxicity, liver infection and/or heart failure. To present a more realistic view of the true VOD incidence only cases of definite VOD that required any kind of medical intervention were recorded for the purpose of our study. Cases of mild severity or uncertain cases that resolved spontaneously without any intervention were not included in our analysis.
No type of prophylaxis for VOD was administered to any of our patients. Liver biochemistry was included in daily monitoring. Ursodeoxycholic acid 250 mg × 3 daily per os was started in case of liver biochemistry abnormalities and continued until complete resolution. Ursodeoxycholic acid at the same dose was administered as part of the treatment in patients with VOD.
Statistical analysis
Non-relapse mortality (NRM) was defined as mortality not directly associated with relapse or progression of the original disease. Survival was calculated from the time of transplant until the time of death from any cause. Cumulative incidence of VOD was calculated using a competing risk model where death before day +30 from causes unrelated to VOD was considered as the competing event. Similarly, cumulative incidence of VOD-related mortality was estimated using the same model where death before day +100 from any cause not directly related to VOD was considered as a competing event. Statistically significant differences in the cumulative incidences between groups in the presence of competing risks were assessed by using the Gray's test. In multivariate analysis, the following variables were entered: age of recipient (above vs below median), sex, disease risk status, year of transplant (before vs after 2004), donor status, previous myeloablative conditioning, pre-existing liver disease and route of BU administration. Fine and Gray's regression model was used for multivariate analysis. For statistical analysis the easy R software (Auckland University, Auckland, New Zealand) was used. 7 
RESULTS
Incidence of VOD and risk factors
In total, VOD developed in 24 out of 271 patients. The cumulative incidence of VOD in the whole cohort of 271 patients was 8.5% (95% confidence interval (CI), 5.8-12.6%). Clinical characteristics of the 24 patients with VOD are shown in Table 1 . Clinical and/or laboratory signs of VOD occurred in a median of 3 days postgraft infusion (range, 0-24). There was no case of late-onset VOD in this cohort of patients. Moderate and severe VOD was observed in 20 (7.4%) and 4 (1.5%) patients, respectively.
In univariate and multivariate analysis, disease status pretransplant, age of recipient, sex of recipient, previous autologous SCT, donor type, donor-recipient match and year of transplant were not associated with VOD incidence. In multivariate analysis, the only variable associated with VOD incidence was the route of BU administration. In more detail, BU when administered i.v. was statistically associated with significantly reduced incidence of VOD, in comparison with per os administration of BU (HR = 0.34; 95% CI, 0.13-0.87; P = 0.025). The cumulative incidence of VOD was 11.7% (95% CI, 7.3-18.5%) and 5.3% (95% CI, 2.5-10.8%) in the groups of patients who received BU per os and i.v., respectively (Figure 1 ).
VOD outcome All patients were managed initially with ursodeoxycholic acid, fluid restriction and diuretics. Four patients with severe VOD developed multiorgan failure and were managed with mechanical ventilation and renal dialysis. None of our patients received any other VODspecific treatment such as defibrotide or recombinant tissue plasminogen activator. VOD resolved in 20 out of 24 patients in a median of 21 days (range, 8-82). All four patients with severe VOD died before day 100 and before VOD resolution. The cause of death was multiorgan failure directly attributed to VOD. For the whole cohort of our patients, the overall cumulative incidence of VOD-related mortality was 1.4% (95% CI, 0.5-3.9%). 100-Day NRM The probability of NRM at 100 days was significantly increased in patients with VOD as compared with the cohort of patients without VOD. In more detail, 100-day NRM was estimated at 41% and 21% in patients with and without VOD, respectively (P = 0.02) (Figure 2) . In multivariate analysis, donor-recipient mismatch (HR = 3.9; 95% CI, 1.9-7.8; P o 0.0001), high-risk disease (HR = 1.7; 95% CI, 1.1-2.9, P = 0.03) and VOD (HR = 2.3; 95% CI, 1.1-4.6; P = 0.02) were statistically associated with significantly increased 100-day NRM.
DISCUSSION
VOD is a serious and potentially lethal complication occurring early after SCT. VOD is the result of sinusoidal endothelial and hepatocyte cell damage in the centrilobular zone of the liver acinus caused by the conditioning regimen. In severe cases, it can lead to complete sinusoidal lumen occlusion, hepatocellular necrosis due to ischemic injury, liver and multiorgan failure and death. 8 In a prospective study conducted by European Group for Blood and Marrow Transplantation, the reported incidence of VOD was estimated at 3.1% and 8.9%, post autologous and allo-SCT, respectively. 5 There is a significant trend for lower incidence of VOD during recent years and most probably the lower incidence is attributed to many factors such as better supportive measures, the use of high-resolution typing in selection of unrelated donors, the i.v. use of BU and the increasing use of RIC regimens. 9 Among the various risk factors associated with increased incidence of VOD, intensity of the conditioning regimen and pre-existing liver disease is of the most important. In a recent study by Carrera et al., 9 the use of myeloablative conditioning was identified as the most predictive variable for increased incidence of VOD, in multivariate analysis. 9 In this study, 452 consecutive patients were transplanted in a single institution since 1997. The cumulative incidence of VOD was 8% and 2% after myeloablative conditioning and RIC conditioning, respectively, and this difference was statistically significant. However, it should be noted that BU was included in the conditioning in only 26 out of 142 patients who underwent allo-SCT using an RIC regimen, and this might be the reason of the low incidence (2%) of VOD observed after RIC regimens.
On the contrary, VOD is practically absent in allo-SCT after truly non-myeloablative conditioning as is the case with TBI 2 Gy ± fludarabine.
10
A major issue that complicates the interpretation of data regarding incidence of VOD after RIC is the heterogeneity in the intensity of the various regimens included in RIC category. In a previous study, Ramasamy et al. 11 reported on the incidence of VOD after allo-SCT using various RIC regimens in a cohort of 237 patients. The cumulative incidence of VOD after RIC was estimated at 5.7% and was significantly reduced as compared with the incidence of VOD (11.9%) observed after myeloablative conditioning regimen in patients transplanted in the same institution during the same period. 11 However, in the study by Ramasamy et al., 11 three different RIC regimens were used and in approximately 30% of patients BU was not included in conditioning regimen. To our knowledge, our study is the first published study reporting on the incidence and outcome of VOD in a large cohort of 271 patients with hematologic malignancies who were treated with the same RIC regimen in a single institution and the first to compare oral vs i.v. BU. Using the Seattle criteria, the observed cumulative incidence of VOD was 8.5%. However, the incidence of severe VOD was very low as it was observed in only 4 out of 24 patients with VOD, for a cumulative incidence of severe VOD as low as 1.4%. In multivariate analysis, BU administered per os was found as the only variable statistically associated with significantly increased incidence of VOD.
Although in our study the incidence of severe VOD was very low (4 out of 271 patients), the overall mortality in this cohort of patients was 100% (four out of four patients). All patients with VOD received ursodeoxycholic acid and supportive treatment. Currently, defibrotide is the only agent with proven efficacy in the prevention and treatment of established severe VOD. The efficacy of defibrotide in the treatment of VOD has been tested in phase II and III studies. 12, 13 Data from these trials showed that the probability of achieving complete clinical resolution of severe VOD and the 100-day mortality was 35% and 60%, respectively.
Patients with VOD have a multisystem disorder of endothelial dysfunction resulting in increased mortality not directly attributed to the VOD process itself.
14 Therefore, 100-day NRM is increased even in patients with mild to moderate forms of the disease who finally achieve complete clinical resolution of VOD. In accordance with the previous and despite the fact that the incidence of severe VOD in our study was very low, the presence of VOD was statistically associated with significantly increased 100-day NRM. It is important to note that none of our patients received VODspecific treatment such as defibrotide and this fact might explain the high mortality rate in cases with severe VOD.
In conclusion, VOD remains a serious complication of allo-SCT with the use of RIC regimens containing BU. Although the incidence is low, VOD is associated with significantly increased 100-day NRM, whereas the overall mortality in patients with severe forms of the disease remains unacceptably high and therefore newer treatment modalities are warranted for this population including novel agents such as defibrotide. 
